Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations improves diagnosis, prognosis and effective therapy selection. This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels. Such panels enable a relatively inexpensive and rapid analysis of various aberrations with clinical impact specific to particular diagnoses. In this review, we discuss the experimental approaches and bioinformatic strategies available for the development of an NGS panel for a reliable analysis of selected biomarkers. Compliance with defined analytical steps is crucial to ensure accurate and reproducible results. In addition, a careful validation procedure has to be performed before the application of NGS targeted assays in routine clinical practice. With more focus on bioinformatics, we emphasize the need for thorough pipeline validation and management in relation to the particular experimental setting as an integral part of the NGS method establishment. A robust and reproducible bioinformatic analysis running on powerful machines is essential for proper detection of genomic variants in clinical settings since distinguishing between experimental noise and real biological variants is fundamental. This review summarizes state-of-the-art bioinformatic solutions for careful detection of the SNV/Indels and CNVs for targeted sequencing resulting in translation of sequencing data into clinically relevant information. Finally, we share our experience with the development of a custom targeted NGS panel for an integrated analysis of biomarkers in lymphoproliferative disorders.

Center of Molecular Medicine Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Hematology University Hospital Schleswig Holstein Kiel Germany

Department of Internal Medicine Hematology and Oncology Faculty of Medicine and University Hospital Brno Masaryk University Brno Czech Republic

Department of Medical Genetics and Genomics Faculty of Medicine and University Hospital Brno Masaryk University Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc21018055

003      

CZ-PrNML

005      

20210729104210.0

007      

ta

008      

210726s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.7717/peerj.10897 $2 doi

035    __

$a (PubMed)33850640

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Hynst, Jakub $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic

245    10

$a Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application / $c J. Hynst, V. Navrkalova, K. Pal, S. Pospisilova

520    9_

$a Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations improves diagnosis, prognosis and effective therapy selection. This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels. Such panels enable a relatively inexpensive and rapid analysis of various aberrations with clinical impact specific to particular diagnoses. In this review, we discuss the experimental approaches and bioinformatic strategies available for the development of an NGS panel for a reliable analysis of selected biomarkers. Compliance with defined analytical steps is crucial to ensure accurate and reproducible results. In addition, a careful validation procedure has to be performed before the application of NGS targeted assays in routine clinical practice. With more focus on bioinformatics, we emphasize the need for thorough pipeline validation and management in relation to the particular experimental setting as an integral part of the NGS method establishment. A robust and reproducible bioinformatic analysis running on powerful machines is essential for proper detection of genomic variants in clinical settings since distinguishing between experimental noise and real biological variants is fundamental. This review summarizes state-of-the-art bioinformatic solutions for careful detection of the SNV/Indels and CNVs for targeted sequencing resulting in translation of sequencing data into clinically relevant information. Finally, we share our experience with the development of a custom targeted NGS panel for an integrated analysis of biomarkers in lymphoproliferative disorders.

655    _2

$a časopisecké články $7 D016428

700    1_

$a Navrkalova, Veronika $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic

700    1_

$a Pal, Karol $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany

700    1_

$a Pospisilova, Sarka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine-Hematology and Oncology, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic $u Department of Medical Genetics and Genomics, Faculty of Medicine and University Hospital Brno, Masaryk University, Brno, Czech Republic

773    0_

$w MED00184567 $t PeerJ $x 2167-8359 $g Roč. 9, č. - (2021), s. e10897

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33850640 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20210726 $b ABA008

991    __

$a 20210729104209 $b ABA008

999    __

$a ind $b bmc $g 1676519 $s 1138497

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 9 $c - $d e10897 $e 20210331 $i 2167-8359 $m PeerJ $n PeerJ $x MED00184567

LZP    __

$a Pubmed-20210726